Gene Expression Landscape of Chronic Myeloid Leukemia K562 Cells Overexpressing the Tumor Suppressor Gene PTPRG

Int J Mol Sci. 2022 Aug 31;23(17):9899. doi: 10.3390/ijms23179899.

Abstract

This study concerns the analysis of the modulation of Chronic Myeloid Leukemia (CML) cell model K562 transcriptome following transfection with the tumor suppressor gene encoding for Protein Tyrosine Phosphatase Receptor Type G (PTPRG) and treatment with the tyrosine kinase inhibitor (TKI) Imatinib. Specifically, we aimed at identifying genes whose level of expression is altered by PTPRG modulation and Imatinib concentration. Statistical tests as differential expression analysis (DEA) supported by gene set enrichment analysis (GSEA) and modern methods of ontological term analysis are presented along with some results of current interest for forthcoming experimental research in the field of the transcriptomic landscape of CML. In particular, we present two methods that differ in the order of the analysis steps. After a gene selection based on fold-change value thresholding, we applied statistical tests to select differentially expressed genes. Therefore, we applied two different methods on the set of differentially expressed genes. With the first method (Method 1), we implemented GSEA, followed by the identification of transcription factors. With the second method (Method 2), we first selected the transcription factors from the set of differentially expressed genes and implemented GSEA on this set. Method 1 is a standard method commonly used in this type of analysis, while Method 2 is unconventional and is motivated by the intention to identify transcription factors more specifically involved in biological processes relevant to the CML condition. Both methods have been equipped in ontological knowledge mining and word cloud analysis, as elements of novelty in our analytical procedure. Data analysis identified RARG and CD36 as a potential PTPRG up-regulated genes, suggesting a possible induction of cell differentiation toward an erithromyeloid phenotype. The prediction was confirmed at the mRNA and protein level, further validating the approach and identifying a new molecular mechanism of tumor suppression governed by PTPRG in a CML context.

Keywords: Chronic Myeloid Leukemia; bio-ontologies; differential expression gene analysis; enrichment gene analysis.

MeSH terms

  • Drug Resistance, Neoplasm
  • Gene Expression
  • Genes, Tumor Suppressor
  • Humans
  • Imatinib Mesylate / therapeutic use
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / pathology
  • Phosphoric Monoester Hydrolases / genetics
  • Protein Kinase Inhibitors / therapeutic use
  • Receptor-Like Protein Tyrosine Phosphatases, Class 5 / genetics*
  • Transcription Factors / genetics

Substances

  • Protein Kinase Inhibitors
  • Transcription Factors
  • Imatinib Mesylate
  • Phosphoric Monoester Hydrolases
  • PTPRG protein, human
  • Receptor-Like Protein Tyrosine Phosphatases, Class 5